Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on November 4, 2016. The filing serves to announce the company's financial and operational results for the quarter ended September 30, 2016. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this Form 8-K.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms that results for the quarter ended September 30, 2016, have been issued.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, risks, contingencies, or unusual items. It explicitly states that the information in this report, including the press release, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the correct registrant name is PharmAthene, Inc., as the input metadata incorrectly listed Altimmune, Inc.
- Review Exhibit 99.1 (the press release) for actual financial figures, as they are absent from this summary text.
- Confirm the reporting period is the quarter ended September 30, 2016.
- Note that this document is a notification of results rather than a detailed financial statement.